Familial adenomatous polyposis
Conditions
Interventions
Aspirin (100 mg/day) enteric-coated tablet
Placebo tablet
Sponsors
Basic and clinical researches on the development of chemopreventive drugs
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: # Patients with previous or existing 100 or more colorectal adenomas, or those with detrimental APC gene # Patients with at least 2 cm of rectal mucosa left intact # Patients who are able to undergo colonoscopy every 6 months # Japanese
Exclusion criteria
Exclusion criteria: # Patients currently taking antithrombotics such as Bayaspirin, Bufferin, Panaldine, Warfarin and Persantin # Patients with gastric ulcer, small intestinal ulcer, anastomotic ulcer or colorectal ulcer # Patients with a history of treatment of gastric or duodenal ulcer (those with successful eradication of Helicobacter pylori and ulcer resolution at S2 are allowed to participate in the study) # Confirmation method Each candidate patient should be interviewed to confirm that he or she has no medical history of gastric or duodenal ulcer and no pain in fasting state. Most recent GIF or UGI findings should be obtained as much as possible. # Patients with bleeding tendency, a platelet count of < 100,000, or with abnormal PT # Patients with any existing cancer at the time of participation in the study. # Patients with known allergy to aspirin. # Patients currently taking anticancer drugs. # Women who are or may be pregnant during the study period. # Patients currently taking NSAIDs at least 3 times weekly, for example, as a analgesic.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Only a reduction in the number of rectal tumors is regarded as the event. | — |
Countries
Japan
Contacts
Public ContactHideki Ishikawa
Kyoto Prefectural University of Medicine Department of Molecular-Targeting Cancer Prevention
Outcome results
None listed